Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial
Lévy Y., Lacabaratz C., Ellefsen-Lavoie K., Stöhr W., Lelièvre J.D., Bart P.A., Launay O., Weber J., Salzberger B., Wiedemann A., Surenaud M., Koelle D.M., Wolf H., Wagner R., Rieux V., Montefiori D.C., Yates N.L., Tomaras G.D., Gottardo R., Mayer B., Ding S., Thiébaut R., McCormack S., Chêne G., Pantaleo G.
Jun 26, 2020 | Publications